Healthcare
Envista Holdings Corp(NVST)
Live Price
Offline$24.86
+0.44% today
1Y Change
+28.48%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $4.29B
- Revenue Growth
- +8.3%
- EPS Growth
- +104.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Envista Holdings Corp (NVST) is a Healthcare stock with a market cap of $4.29B and listed on NYSE. The stock last traded around $24.86 and up 28.5% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +104.3%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS +104.3%, free cash flow -23.9% with operating margin 8.5% and ROIC 1.3%. Valuation already assumes a fairly strong business story at P/E 92.1 and price/sales 1.6. Stock Foundry combines NVST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.3% vs +7.6% peer median
Operating Margin
Below sector median
+8.5% vs +19.4% peer median
P/E
Above sector median
92.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.3% and EPS at +104.3%, with operating margin around 8.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -0.2% | -1.8% | -4.9% |
2026 Feb 5, 2026 | +18.8% | +17.8% | +16.4% | +8.7% |
2025 Oct 29, 2025 | +18.5% | +0.8% | +0.9% | +5.1% |
Benchmark Edge
NVST vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVST
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVST Max Drawdown
-25.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVST and SPY.
Company Overview
Envista Holdings Corp
New York Stock Exchange
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
- Leadership
- Paul A. Keel
- IPO Date
- Sep 18, 2019
- Employees
- 12.3k
- Street Address
- 200 S Kraemer Blvd Bldg E
- Mailing
- Brea, CA, 92821-6208
- Region
- Brea, CA, US
- Reporting Currency
- USD
- Investor Line
- 17145167774
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 92.1
- EV/EBITDA
- 13.5
- Price/Sales
- 1.6
- Price/Book
- 1.4
Growth
- Revenue
- +8.3%
- EPS
- +104.3%
- Free Cash Flow
- -23.9%
Profitability
- Gross Margin
- 55.0%
- Operating Margin
- 8.5%
- Net Margin
- 1.7%
- ROE
- 1.5%
- ROIC
- 1.3%
Balance Sheet
- Debt/Equity
- 0.55
- Current Ratio
- 2.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.